Page 7 - Read Online
P. 7

Page 125                 Fanella et al. J Transl Genet Genom 2021;5:124-9  https://dx.doi.org/10.20517/jtgg.2021.11

               INTRODUCTION
               Neurofibromatosis type 1 (NF1) (MIM No. 162200) is a complex autosomal dominant disorder involving
               multiple body systems (with an estimated prevalence of 1/2500-1/3000 individuals). Neurofibromin protein,
               encoded by NF1 gene, is highly expressed in neurons, glia, Schwann cells, and the early stage of melanocyte
                          [1,2]
               development . Neurofibromin inhibits the activity of the proto-oncogene Ras, catalyzing the guanosine
               triphosphate (GTP)-bound Ras hydrolysis to guanosine diphosphate (GDP)-bound Ras and thus preventing
                           [3]
               tumor growth . In NF1, the absence of neurofibromin leads to unopposed GTPase activity, releasing the
               downstream signals involved in cell proliferation and differentiation.

               According to the National Institutes of Health (NIH) diagnostic criteria , NF1 clinical diagnosis is based on
                                                                           [4]
               the presence of at least two typical features or only one symptom with an affected first-degree relative.
               Characteristic NF1 findings are hyperpigmented skin markings or café-au-lait macules (CALMs), which
               typically develop in the first 2 years of life, axillary or inguinal freckling, distinctive bone anomalies, Lisch
               nodules, and neurofibromas. Neurologic features, in particular mild neurocognitive deficits and epilepsy,
                                                         [5,6]
               have been also frequently described in  NF1 . A remarkable phenotype lacking both cutaneous
               neurofibromas  and  visible  plexiform  neurofibromas  has  been  associated  with  the  in-frame
               c.2970_2972del  and the missense mutation at codon Arg 1809  mutations.
                                                                     [10]
                            [7-9]
               Here, we describe, for the first time, an interesting milder variant manifesting with idiopathic generalized
               epilepsy (IGE) and typical pigmentary skin manifestations.

               CASE REPORT
               We report the case of a 27-year-old, right-handed man, who first presented typical absence seizures at the
               age of 4. At that time, the electroencephalogram (EEG) showed 3-Hz generalized spike-and-wave
               discharges. At 16 years, he was hospitalized following the occurrence of a generalized tonic-clonic seizure.
               During his hospital stay, the EEG confirmed the previous findings and a brain magnetic resonance imaging
               (MRI) showed focal bilateral subcortical signal alterations in the T2-weighted sequences [Figure 1A], which
               had completely disappeared by the time the patient undertook a follow-up MRI scan 4 months later
               [Figure 1B]. In addition, during hospitalization the physicians also observed pigmentary manifestations
               similar to CALMs - eight café-au-lait macules of 10-20 mm located on the arms and the trunk - although no
               other feature suggestive of NF1 was detected.

               At the age of 26, the patient came to our observation for seizure persistence. He underwent a video-EEG
               recording that showed the presence of generalized epileptiform abnormalities [Figure 2]. Brain MRI and
               neurologic  examination  were  normal.  A  complete  neuropsychological  evaluation  (including
               Phonemic/Semantic Alternate Fluency Test, Attentive Matrix, Trail Making Test, Rey Auditory Verbal
               Learning Test, Rey-Osterrieth Complex Figure Test, Short-Story Recall Test, Stroop Test, Raven Colored
               Progressive Matrices, Abstract Verbal Judgment, WAIS-IV Working Memory Scale, Tower of London Test,
               and Ideomotor Apraxia Test) documented a normal cognitive profile except for a slight attention shifting
               deficit. Seizure control was achieved thanks to a polytherapy with valproate 1500 mg/day, zonisamide
               200 mg/day,  and  brivaracetam  150  mg/day.  A  dedicated  team  of  specialists  (i.e.,  orthopedists,
               ophthalmologists, and dermatologists) examined our patient, and were unable to identify other typical
               features of NF1. This included slit-lamp exam for Lisch nodules and plain film radiographs to screen for
               bone dysplasias. Although all the clinical and instrumental evaluations did not reveal other peculiar aspects,
               we performed Next Generation Sequencing (NGS) and Sanger sequencing that allowed us to detect the de
               novo NM_000267.3: c.2970_2972delAAT p.(Met992del) in exon 22 of NF1 gene. Sanger sequencing did not
               detect the deletion in parents.
   2   3   4   5   6   7   8   9   10   11   12